We are testing a new treatment called Xaluritamig for men with newly diagnosed localized intermediate or high-risk prostate cancer. The goal is to see how well it works before surgery.
Health conditions and diseases that the clinical trial is designed to study and treat.
Localized Intermediate or High-Risk Prostate Cancer refers to a type of prostate cancer that is confined to the prostate gland and has a higher likelihood of spreading. It is categorized based on specific risk factors that indicate a more aggressive form of the disease.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.